YTHDF1 and neoplasm: Downregulation of YTHDF1 results in the reduction of antigen cross-presentation and alleviation of the cytotoxic lymphocyte response against tumor antigens in dendritic cells, thereby enhancing the effectiveness of the PD-1 blockade therapy.